Amniotic Suspension Allograft + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Knee Osteoarthritis
Conditions
Knee Osteoarthritis
Trial Timeline
Dec 14, 2020 → Aug 19, 2025
NCT ID
NCT04636229About Amniotic Suspension Allograft + Placebo
Amniotic Suspension Allograft + Placebo is a phase 3 stage product being developed by Organogenesis for Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04636229. Target conditions include Knee Osteoarthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06000410 | Phase 3 | Completed |
| NCT04636229 | Phase 3 | Completed |
Competing Products
20 competing products in Knee Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| UBX0101 | Unity Biotechnology | Phase 2 | 44 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |
| YH23537 + Celecoxib + YH23537 placebo | Yuhan | Phase 2 | 52 |
| YM150 + Warfarin | Astellas Pharma | Phase 2 | 52 |
| ASP7962 + Naproxen + Placebo | Astellas Pharma | Phase 2 | 52 |
| Capsaicin Topical Solution | Astellas Pharma | Approved | 85 |
| CGS-200-1 + CGS-200-5 + CGS-200 Vehicle | Astellas Pharma | Phase 2 | 52 |
| MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Shionogi | Phase 3 | 77 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| V120083 + Naproxen + Placebo | Shionogi | Phase 2 | 52 |
| ONO-4474 + Placebo matching ONO-4474 | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine (DLX) + Placebo (PLA) | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY545694 49 mg + LY545694 105 mg | Eli Lilly | Phase 2 | 52 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |